1
|
Hoffbrand AV. Haematology in the UK: A 60-year personal perspective. EJHAEM 2021; 2:569-576. [PMID: 35844697 PMCID: PMC9175951 DOI: 10.1002/jha2.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 11/09/2022]
Abstract
The advances in understanding the pathogenesis, in the diagnosis and classification of blood diseases and in their treatment that have been achieved over the six decades from 1960 to 2020, are reviewed. Emphasis is given to the new techniques, especially in immunology and molecular biology, that have enabled this remarkable progress. The review also highlights the major contributions of UK haematologists and non-clinical scientists to these advances.
Collapse
|
2
|
|
3
|
Abstract
In at least 50% of patients with suspected deep vein thrombosis, the diagnosis is not confirmed by objective testing. The addition of impedance plethysmography and real-time B-mode ultrasound with color-enhanced Doppler imaging to the available diagnostic modalities has altered the approach to clinical evaluation. Pharmacologic treatment has evolved to place emphasis on the use of subcutaneous heparins of greater efficacy and the reduction of hemorrhagic risk with the use of the INR system when warfarin is recommended for long-term therapy. Use of new approaches for diagnosis and management offers the potential of more prompt and accurate diagnosis, more effective therapy, and a reduction in the incidence of pulmonary thromboembolism.
Collapse
Affiliation(s)
- W F Baker
- Department of Medicine, University of California at Los Angeles Center for the Health Sciences
| | | |
Collapse
|
4
|
Racanelli A, Fareed J. Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine. Thromb Res 1992; 67:263-73. [PMID: 1332215 DOI: 10.1016/0049-3848(92)90145-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
To study whether the ex vivo activity of heparin and Fraxiparin correlates to and predicts the extent of blood loss induced by the heparins (pre- and post neutralization by protamine), a rat tail transection model and a rabbit ear bleeding model were used. In the rat model heparin (2 mg/kg i.v.) significantly prolonged the bleeding time, while this dose of Fraxiparin had no effect. In the rabbit ear blood loss model, heparin (2 mg/kg i.v.) produced significant increases in blood loss while Fraxiparin (2 mg/kg i.v.) produced approximately 30% of the blood loss induced by heparin. Equigravimetric protamine reduced the heparin-induced blood loss by approximately 50%, however, significant blood loss, thrombin time and Heptest activity remained. Heparin and Fraxiparin (3 mg/kg s.c.) did not cause any increased bleeding. While, all activities of heparin were completely neutralized by protamine, the Heptest activity of Fraxiparin was resistant to neutralization. The ex vivo activity of heparins after neutralization by protamine does not correlate to the extent of blood loss which suggests it may not be necessary to neutralize all ex vivo activities of the heparins to baseline values to be assured that blood loss is reversed.
Collapse
Affiliation(s)
- A Racanelli
- Loyola University Medical Center, Maywood IL 60153
| | | |
Collapse
|
5
|
Laforest MD, Colas-Linhart N, Guiraud-Vitaux F, Bok B, Bara L, Samama M, Marin J, Imbault F, Uzan A. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol 1991; 77:201-8. [PMID: 1848441 DOI: 10.1111/j.1365-2141.1991.tb07978.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
For a better understanding of low molecular weight heparin pharmacokinetics, 99m technetium labelled heparin and enoxaparin were injected intravenously to four normal volunteers, after approval by the Ethics Committee and preliminary animals studies. In vitro and in vivo, the labelled products proved to be stable and identical to the non-labelled drugs. Radioactivity curves in blood, organs and urines were similar for both products. Anti Xa plasma half-life was 3 times longer for enoxaparin than for heparin. Anti IIa plasma half-lives were similar. However, radioactivity persisted much longer than biological activities for both products. After chromatography, most of the radioactivity was bound to AT III, where an anti Xa activity peak was also detected. The anti Xa activity peak seen after adding AT III to plasma was much higher with heparin than with enoxaparin. In urine, biological activities, measured with AT III supplementation, were higher with enoxaparin than with heparin. These results suggest that phenomena other than biodistribution are responsible for the differences in pharmacokinetics observed between these two products. The two most likely explanations are differences in metabolism and/or a release of an endogenous factor.
Collapse
Affiliation(s)
- M D Laforest
- Service de Médecine Nucléaire, Hôpital Beaujon, Clichy, France
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ofosu FA, Barrowcliffe TW. Mechanisms of action of low molecular weight heparins and heparinoids. BAILLIERE'S CLINICAL HAEMATOLOGY 1990; 3:505-29. [PMID: 1703023 DOI: 10.1016/s0950-3536(05)80016-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
7
|
Gallus AS. Anticoagulants in the prevention of venous thromboembolism. BAILLIERE'S CLINICAL HAEMATOLOGY 1990; 3:651-84. [PMID: 2148697 DOI: 10.1016/s0950-3536(05)80023-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
For 50 years, the key to successfully preventing venous thrombosis (VT) or pulmonary embolism (PE) among high-risk patients has been the judicious use of anticoagulants: first through full doses of oral anticoagulants and more recently through low-dose heparin prophylaxis. Low-dose heparin has become the standard of comparison for other preventive methods, since it is relatively safe and simple, its ability to prevent approximately 65% of the subclinical VT found by leg scanning after elective general surgery is well known, and recent meta-analysis of the many pertinent published clinical trials (large and small) strongly suggests a much greater benefit: a 65% reduction in the risk of postoperative death from major PE. In addition, there are trials that have also found low-dose heparin to be effective in general medical patients, although its value in this clinical setting is much less well documented. Although several effective approaches other than low-dose heparin are available, many of these tend to be either more cumbersome (intermittent external leg compression) or probably less powerful (graded pressure elastic stockings). There are situations where low-dose heparin prophylaxis fails, most obviously after orthopaedic surgery where the use of more complex regimens, including adjusted-dose heparin treatment and various schedules of warfarin prophylaxis, becomes appropriate. Recent progress has come from the intensive clinical exploration of various low molecular weight heparin fractions or fragments which appear to be effective after once daily administration to general surgical patients and show great promise of effectiveness and safety after hip surgery. The level of warfarin effect needed for VT prophylaxis has also been reinvestigated, with trials suggesting a need for less warfarin and a lower prothrombin time effect than was previously thought to be appropriate. Given that any attempts to minimize mortality from PE in hospital patients must rely on the widespread and systematic use of simple, safe, and cost-effective preventive methods, it is hoped that these advances will help move anticoagulant prophylaxis further out of the realm of clinical research and into that of common clinical practice.
Collapse
|
8
|
Colas Linhart N, Laforest MD, Guiraud-Vitaux F, Gardin I, Petiet A, Berthelot JL, Bok B. Pharmacokinetics and tissue distribution of 99mTc-labelled enoxaparin in the rat: evaluation of dosimetry parameters. Biomed Pharmacother 1990; 44:317-23. [PMID: 2171691 DOI: 10.1016/0753-3322(90)90135-v] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
A low molecular weight heparin, enoxaparin, was labelled with 99mTc and the characteristics of the labelled compound determined. In vitro the stability, and labelling efficiency (98%) of the labelled drug were excellent. Rats were injected with 99mTc-enoxaparin to study pharmacokinetics and distribution. The results were used to calculate dosimetric estimates which are a prerequisite for pharmacokinetic studies on labelled LMWH (low molecular weight heparin) in human subjects. Biodistribution studies showed preferential liver and spleen accumulation. But the doses absorbed by these target organs remained below the upper limits of the dose received by a patient undergoing hepatic scintigraphy.
Collapse
Affiliation(s)
- N Colas Linhart
- Laboratoire de Biophysique, Faculté Xavier Bichat, Paris, France
| | | | | | | | | | | | | |
Collapse
|
9
|
Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, Wiesel ML, Kher A, Barbier P, Cazenave JP. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988; 18:561-7. [PMID: 2852111 DOI: 10.1111/j.1365-2362.1988.tb01268.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Eighty patients undergoing pelvic or abdominal surgery for cancer were randomized in two groups for prevention of postoperative thromboembolism: 40 patients received a 15,000 IU day-1 Calciparine prophylaxis and 40 patients a 5000 anti-Xa U/d Fragmin prophylaxis for 10 days. In the Calciparine group, two patients (5%) developed postoperative pulmonary embolism but none developed it in the Fragmin group. Two patients in the Fragmin group (5%) developed isotopic DVT, which was not confirmed by phlebography. There was no deep vein thrombosis of the lower limbs in the two groups. Important postoperative bleeding (one patient in the Calciparine group and two patients in the Fragmin group) was similar in both groups. Moderate and minor bleeding were significantly lower in the Fragmin group. Haemoglobin and haematocrit changes, total blood loss and transfusion requirements were not different in both groups. It is concluded that, over a 10-day period, one daily 5000 U Fragmin prophylaxis was as effective and safe as three daily 5000 IU Calciparine injections.
Collapse
Affiliation(s)
- J P Fricker
- Centre Régional de Lutte contre le Cancer Paul Strauss, Strasbourg, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mastacchi R, Barbanti M. Inactivation of the heparin anticoagulant activity by rat kidney lysosomal enzymes. Thromb Res 1987; 47:101-6. [PMID: 2821647 DOI: 10.1016/0049-3848(87)90245-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
11
|
Dawes J, Prowse CV, Pepper DS. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 1986; 44:683-93. [PMID: 2433788 DOI: 10.1016/0049-3848(86)90169-6] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Unfractionated heparin, pentosan polysulphate (SP54) and the low molecular weight heparins CY216 and CY222 were injected subcutaneously at a minimum of weekly intervals into 5 healthy volunteers. The dose was 75 mg in all cases. Concentrations of administered glycosaminoglycan in serial plasma samples and voidings of urine were measured using a competitive binding assay, and biological activity was assessed in plasma using APTT and anti-Xa clotting assays. There was wide individual variation in the absorption of unfractionated heparin as indicated both by the maximal plasma concentrations reached 2-3 h after injection and by the area under the concentration vs. time curve. The efficiency of absorption increased and the individual variation decreased with decreasing molecular weight of the administered glycosaminoglycan. Urinary excretion correlated with plasma concentration, and recovery in the urine also increased with decreasing molecular weight. Similar patterns of uptake and clearance were indicated by the APTT and competitive binding assays, but anti-Xa clotting activity could be detected in the plasma after clearance of the administered glycosaminoglycan.
Collapse
|
12
|
Bârzu T, Van Rijn JL, Petitou M, Molho P, Tobelem G, Caen JP. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986; 238:847-54. [PMID: 2432885 PMCID: PMC1147213 DOI: 10.1042/bj2380847] [Citation(s) in RCA: 82] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The specificity of endothelial binding sites for heparin was investigated with heparin fractions and fragments differing in their Mr, charge density and affinity for antithrombin III, as well as with heparinoids and other anionic polyelectrolytes (polystyrene sulphonates). The affinity for endothelial cells was estimated by determining I50 values in competition experiments with 125I-heparin. We found that affinity for endothelial cells increases as a function of Mr and charge density (degree of sulphation). Binding sites are not specific receptors for heparin. Other anionic polyelectrolytes, such as pentosan polysulphates and polystyrene sulphonates, competed with heparin for binding to endothelial cells. Fractions of standard heparin with high affinity for antithrombin III also had greater affinity for endothelium. However, these two properties of heparin (affinity for antithrombin III and affinity for endothelial cells) could be dissociated. Oversulphated heparins and oversulphated low-Mr heparin fragments had lower anticoagulant activity and higher affinity for endothelial cells than did their parent compounds. Synthetic pentasaccharides, bearing the minimal sequence for binding to antithrombin III, did not bind to endothelial cells. Binding to endothelial cells involved partial neutralization of heparin. Bound heparin exhibited only 5% and 7% of antifactor IIa and antifactor Xa specific activity, respectively. In the presence of 200 nM-antithrombin III, and in the absence of free heparin, a limited fraction (approx. 30%) of bound heparin was displaced from endothelial cells during a 1 h incubation period. These data suggested that a fraction of surface-bound heparin could represent a pool of anticoagulant.
Collapse
|
13
|
Priollet P, Roncato M, Aiach M, Housset E, Poissonnier MH, Chavinie J. Low-molecular-weight heparin in venous thrombosis during pregnancy. Br J Haematol 1986; 63:605-6. [PMID: 3730290 DOI: 10.1111/j.1365-2141.1986.tb07540.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
14
|
Messmore HL, Hirsh J. Clinical efficacy of heparin fractions: issues and answers. Crit Rev Clin Lab Sci 1986; 23:77-94. [PMID: 2419035 DOI: 10.3109/10408368609165796] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The recent development of heparin fractions and fragments for clinical use has created the prospect of some new agents at our disposal for the treatment of thrombotic disorders. The development of a drug that will block thrombosis but will not impair hemostasis now appears to be a possibility. Due to lack of understanding of all of the mechanisms of the pathology of thrombosis, we are not certain what the properties of the ideal anticoagulant should be. Of the heparins and heparin fractions, fragments, and heparinoids now available to us, we have yet to fully understand the mechanism of their pharmacologic activity. It has been amply demonstrated that decreasing the average molecular weight decreases the antithrombin activity while retaining the anti-Xa activity of heparin derivatives. Studies on animal models have proven the antithrombotic potency of some of these low molecular weight heparins to be equal to that of unfractionated heparin. There has been some evidence that these fractions are less likely than unfractionated heparin to cause hemorrhage in animal models as well as in at least one human clinical trial. A recently published human clinical trial revealed an unexpected incidence of hemorrhage following major surgery when a certain heparin fraction was given as prophylaxis against thrombosis. We are desperately in need of heparin derivatives, heparinoids or other anticoagulants that can be used in place of standard heparin in patients who are allergic to heparin or who have heparin-induced thrombocytopenia. Patients with these problems not infrequently require cardiopulmonary bypass surgery in which the use of heparin has been mandatory. There is now evidence from animal and human studies that such a procedure is possible with a heparin fraction or a heparinoid. This is true for hemodialysis as well. Studies in progress offer hope that a low molecular weight fragment with potent anti-Xa activity will not cause thrombocytopenia in patients with heparin-induced thrombocytopenia. Whether this agent, a pentasaccharide, will have sufficient antithrombotic potency for clinical use remains an important question. An important property of some of the newer heparin fractions is a prolonged duration of action which may permit fewer doses, thus reducing the cost as well as patient discomfort and inconvenience.
Collapse
|
15
|
Cumming AM, Jones GR, Wensley RT, Cundall RB. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins. Thromb Res 1986; 41:43-56. [PMID: 3961726 DOI: 10.1016/0049-3848(86)90278-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
This study was carried out to investigate the effects on the activated partial thromboplastin time test (APTT) when heparin in plasma was neutralized with protamine, Polybrene(R), poly-DL-lysine, or heparin neutralizing activity (HNA) extracted from platelets; or removed by means of the anion exchange resins TEAE cellulose or ECTEOLA cellulose. The effect on the APTT of adding the polycations protamine, Polybrene or poly-DL-lysine to citrated plasma was examined. The formation of heparin/polycation complexes was studied by means of their light scattering properties. The low yields of platelet HNA obtained excluded this from practical use as an in vitro heparin antagonist. ECTEOLA cellulose was unable to remove plasma heparin at levels as low as 1 U/ml by the technique employed. TEAE cellulose was able to efficiently remove at least 40 U of heparin from 1 ml of plasma but also caused a non-specific prolongation of the APTT. The polycations protamine, Polybrene, and poly-DL-lysine, possessed clot promoting activity at low concentrations and acted as anticoagulants in their own right at higher concentrations. At a plasma heparin concentration of 4 U/ml, protamine was the most efficient neutralizer of heparin, while at 10 U/ml, Polybrene was the most effective in this respect. It was concluded that care must be taken in the interpretation of the APTT after heparin neutralization or removal as heparin antagonist induced non-specific effects may be present.
Collapse
|